Introduction
Different species of the Ascomycetous yeast-like fungus Pneumocystis asymptomatically infect/colonize numerous healthy mammalian hosts and in immune compromised mammals (including humans) can cause a potentially life-threatening pneumonia (PCP). The organism is host-obligate and species specific: it cannot be grown outside the host and organisms from one host cannot infect other mammalian hosts [1] .
Pneumocystis was identified in 1909 by Chagas, who mistakenly described it as part of the life cycle of the protozoan parasite Trypanosoma cruzii. It was first recognized as a human pathogen when it was described as the cause of "interstitial plasma cell pneumonia" among premature/malnourshised infants in European orphanages immediately after WW2. In the 1960s and 1970s descriptions of PCP were mainly in children with congenital immunodeficiency and also among adults/children with acquired immunological deficits resulting from malignancy (specifically, glioma, and acute leukemia) or its treatment (with glucocorticoids and purine analogues). The advent of organ transplantation and iatrogenic immunosuppression in the 1960s was associated with reports of PCP among this patient population.
In 1981 description of PCP in 15 previously healthy men who had sex with other men and/or who were injection drug users heralded the advent of the global HIV/AIDS pandemic [2] [3] . Despite the availability of prophylaxis and of combination antiretroviral therapy (cART) PCP remains an important clinical presentation among HIV-infected persons [4] .
Epidemiology of HIV-associated PCP

Before the onset of the AIDS epidemic PCP was uncommon in the United
States; between November 1967 and December 1970 194 patients were reported to Centers for Disease Control [5] , and in the 1970s fewer than 100 cases per year were seen in the United States. During the early years of the AIDS epidemic, PCP accounted for two thirds of AIDS-defining illness in patients in the United States, and an estimated 75% of HIV-infected patients developed PCP during their lifetime [6] [7] ; rates of PCP were as high as 20 per 100 person-years among those with CD4 cell counts <200 cells/µL [7] [8] .
The first substantial decline in the incidence of PCP occurred after the introduction of anti-Pneumocystis prophylaxis in 1989 [9] . In the United States because of an increasing incidence of AIDS from 1989 to 1992, absolute numbers of reported cases of PCP as an AIDS-defining illness remained stable, but the percentage with PCP declined, from 53% in 1989 to 42% in 1992, respectively [7] .
The advent of cART resulted in further declines in rates of PCP and other opportunistic infections [7] [10] [11] . Several large, multicenter studies have tracked the incidence and epidemiologic features of PCP in the era of cART. Data from the Adult and Adolescent Spectrum of HIV Disease (ASD) study showed a marked reduction in incidence of all opportunistic infections in 1996 and 1997, when cART first became widely available; from 1992 to 1995 cases of PCP declined by 3.4% per year, and from 1996 to 1998 declined by 21 .5% per year [7] [11]. Multicenter AIDS Cohort Study also showed a marked reduction in opportunistic infections after introduction of cART [12] In Europe, the EuroSIDA study has examined changes in incidence of AIDSdefining disease before and after cART was introduced (1994-1998) and found results similar to those in the United States. The incidence of PCP fell from 4.9 cases per 100 person-years before March 1995 to 0.3 cases per 100 person-years after March 1998 [13] [14] .
Despite these improvements, data from the Hospital Outpatient study (HOPS) shows that PCP remains the second most common AIDS-defining opportunistic infection in the United States; in 1994-1997 the incidence was 29.9 per 1000 personyears, and fell to 7.7 and 3.9 per 1000 person-years, in 1998-2002 and 2003-2007, respectively [14] . In the United Kingdom PCP was the commonest AIDS-defining illness in the decade 2001-2010 [16] .
In the United States, Western Europe and Australasia PCP still occurs among HIV-infected persons despite the availability of cART and anti-Pneumocystis prophylaxis. The ASD study examined use of PCP prophylaxis among HIV-infected adults who developed PCP during 1999-2001 [12] . More than 43% of PCP cases occurred in persons not receiving medical care, the majority of who were likely not 5 known to be HIV-infected, and a further 41% were prescribed prophylaxis but were either non-adherent with treatment, or PCP developed despite treatment adherence.
Possible explanations for PCP in this group include decreased efficacy of prophylaxis among those with low CD4 counts and development of drug-resistant Pneumocystis.
An additional 9.6% were under medical care but did not receive prophylaxis, based on current recommendations (i.e. CD4 count >200 cell/ul, or >14% of total lymphocyte count) [17] .
In the pre-cART era the greatest risk factor for PCP in an HIV-infected person was a CD4 cell count <200 cells/µL; this remains an important risk factor in the cART era. The lower the CD4 count falls below 200 cells/µL the risk for PCP increases exponentially [18] . Those who develop PCP despite receipt of cART usually have a low CD4 count. In the ASD study the CD4 count among persons developing PCP while receiving cART was low (median=29 cells/µL), and was lower among those not taking cART (median=13 cells/µL) [11] . The prospective pan-European EuroSIDA study reported that the median CD4 count was 30 cells/µL among persons developing PCP while receiving cART, and was similar among those not receiving cART who got PCP [8] . Patients without improvement in their CD4 count after starting cART remain at risk for PCP. One recent study showed that approximately 5% of HIV-infected persons have a CD4 count >200 cells/µL at presentation with PCP [19] .
Other clinical risk factors for development of PCP include gender, race or ethnicity, and risk factor for HIV acquisition. Men are more likely than women to develop PCP [17] ; one study demonstrated that African Americans have a lower risk for PCP than white persons [17] but this finding has not been replicated [10] MSM appear to be at equal risk, when compared with other risk exposure groups [10] .
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PCP still occurs frequently among HIV-infected patients in many parts of the developing world [20] . Studies from Thailand show the prevalence of PCP is up to 40% [21] . Central and South America also report large numbers of PCP cases. One Brazilian study found that 55% of HIV-infected persons with respiratory symptoms had PCP [22] , another study from Mexico reported a 24% PCP prevalence [23] .
By contrast, PCP has until recently been thought to be rare in African adults.
However, high rates of anti-Pneumocystis antibodies among African children suggest that exposure to the organism is common, and PCP is a common cause of pneumonia among children in Sub-saharan Africa [24] . PCP might have been underreported in Africa for several reasons. Limited local diagnostic resources, including lack of trained clinical and laboratory personnel and expensive equipment mean that invasive investigations such as induced sputum and bronchoscopic alveolar lavage are less commonly performed, and reliance on empiric therapy of HIV-infected persons with presumed PCP potentially results in under-estimation of the true incidence of PCP. Many HIV-infected African adults may not reach a stage at which they would be susceptible to PCP as these populations have high rates of tuberculosis and bacterial pneumonia that may result in death at higher CD4 counts.
Environmental factors, such as temperature and seasonality, might also contribute to a low rate of PCP in Africa. The population may be more resistant to development of PCP; HIV-infected African Americans have been shown to have lower rates of PCP than white Americans [18] ; or P. jirovecii strains isolated in Africa may be less virulent, a possibility that can only be answered by large-scale molecular epidemiologic studies.
As the AIDS epidemic progresses in Africa most, but not all studies suggest that the incidence of PCP is increasing [20] After inhalation, Pneumocystis eludes the upper airway defenses and deposits in alveoli: where it adheres tightly to alveolar type I cells, and provokes a host inflammatory response [36] . In the majority of hosts with an intact immune system the organism is rapidly coughed out. If the host has any underlying "minor" immune suppression/HIV-associated immunodeficiency, colonization with Pneumocystis ensues [34] [35] . If the host then becomes more immune compromised, by progression of HIV, or by additional therapeutic immune supression then Pneumocystis propagates within the alveoli, and slowly "floods them out." At the same time disruption of the alveolar-capillary membrane, with ventilation-perfusion abnormalities similar to changes seen in acute respiratory distress syndrome, also occur and manifest as impaired gas exchange. These events culminate in presentation with PCP; in humans PCP is caused by Pneumocystis jirovecii;
Pneumocystis carinii is the cause of PCP in rats.
Clinical manifestations
The clinical presentation of PCP among HIV-infected patients is non-specific and can be mimicked by a wide variety of infectious and non-infectious etiologies.
Patients typically present with a triad of progressive exertional dyspnea, nonproductive cough, and fever of several days or weeks duration, which is often associated with an inability to take in a maximum inspiration (not due to pain) [37] [38] . Although a productive cough and chest tightness may occur, purulent sputum should raise suspicion of bacterial infection. Hemoptysis is not a feature.
Among HIV-infected persons, symptoms are usually of longer duration than among medically-immunosuppressed patients [39] . HIV-infected patients frequently have prolonged prodromal periods with subtle clinical manifestations developing over 3-8 weeks, however some individuals present with a fulminant deterioration of symptoms over 7-10 days, or less. On physical examination varying degrees of respiratory distress (tachycardia, central cyanosis) may be evident as well as stigmata of immune suppression, including oral hairy leukoplakia, molluscum contagiousum, seborrhoeic dermatitis and cutaneous Kaposi sarcoma; auscultation of the chest is usually normal; rarely, fine end-inspiratory crackles may be heard.
Diagnosis
Non-invasive investigations
Chest radiology
In early PCP, the chest radiograph may be normal; with later presentations, and with more severe disease, diffuse perihilar interstitial infiltrates are seen ( Figure   1 ). These appearances may progress to diffuse bilateral air space (alveolar) consolidation resembling pulmonary edema. With delayed presentation or untreated severe disease, there may be confluent alveolar shadowing ("white out") throughout Although the chest radiograph is a sensitive way of detecting PCP, it is nonspecific; these typical and atypical radiographic appearances are also seen in other fungal, mycobacterial and bacterial infections, and in non-infectious conditions, such as interstitial pneumonitis and pulmonary Kaposi sarcoma. With treatment of PCP, improvements in the chest radiographic appearances are not usually apparent for 7-10 days. After clinical recovery, some radiographs show residual fibrosis or postinfectious bronchiectasis.
High-resolution computed tomography
This may be useful in the symptomatic patient with suspected PCP who has a normal or equivocal chest radiograph. Patches of "ground glass" shadowing are typical for PCP, but also occur in viral (eg cytomegalovirus, influenza A) or fungal pneumonia and in occult alveolar hemorrhage ( Figure 5 ).
Arterial blood gases
In patients presenting early with PCP, even though the arterial oxygen tension (PaO2) may be normal or near normal, respiratory alkalosis with hypocarbia (indicating hyperventilation) is often detected; hypoxia may occur with progression of the PCP. The alveolaraO2) is widened in >90% of patients with PCP, but this finding, although suggestive, is non-specific as both hypox aO2 gradient also occur in bacterial and mycobacterial infection, non-specific interstitial pneumonitis and pulmonary Kaposi sarcoma.
Exercise oximetry
Among HIV-infected patients, not in receipt of cART, and who have respiratory symptoms, a normal or near-normal chest radiograph and normal resting PaO2 values, exercise-induced arterial desaturation is a sensitive and specific method of detecting PCP. A normal exercise test (without desaturation) virtually excludes the diagnosis.
Pulmonary function testing
Data from the North American Pulmonary Complications of HIV infection
Study suggest that HIV-individuals who are not in receipt of cART and who have rapid rates of decline in DLCO are at an increased risk for development of PCP [18] .
A normal DLCO in an individual who has respiratory symptoms but a normal or 11 unchanged chest radiograph makes the diagnosis of PCP extremely unlikely.
Serum lactate dehydrogenease
An elevated serum lactate dehydrogenase (LDH) level is highly suggestive of PCP in an HIV-infected patient with sub-acute respiratory symptoms [40] . However an elevated serum LDH is non-specific as it is also found in other pulmonary diseases, including pulmonary embolism, non-specific interstitial pneumonitis, fungal, bacterial and mycobacterial pneumonia, as well in extra-pulmonary disease, such as multicentric Castleman disease and lymphoma.
Serum (1-3) ß-D-glucan
Measurement of the fungal cell wall component (1-3) ß-D-glucan (BG) in serum has been used as an adjunctive diagnostic tool for diagnosis of PCP [41] [42].
BG levels are higher among both HIV-infected and uninfected patients with PCP, when compared with symptomatic patients with confirmed alternative diagnoses, including aspergillosis and histoplasmosis. False positive results occur in bacterial pneumonia, patients undergoing hemodialysis, and those who recently received intravenous immunoglobulin. Currently, the serum BG assay appears to be a promising adjunctive non-invasive test for diagnosis of PCP, but further validation is needed before it can it be used to monitor treatment response in PCP, as despite clinical recovery, reductions in BG titer are both delayed and unpredictable [43] .
Plasma/serum S-adenosylmethionine
Pneumocystis lacks S-adenosylmethionine synthetase, is unable to metabolize S-adenosylmethionine (SAM, or Adomet), and so 'scavenges' this from the human host. It was hypothesized that HIV-infected persons with PCP would have low serum/plasma SAM levels. Whereas measurement of plasma SAM levels enabled discrimination between PCP and "other" causes of pneumonia in some studies [44] , one study showed overlapping serum SAM levels [45] . Currently, this this assay lacks clinical diagnostic utility.
Invasive investigations
Sputum induction
Pneumocystis is rarely identified in spontaneously expectorated sputum. 
Video-Assisted thoracoscopic biopsy
This is occasionally performed in HIV-infected patients with suspected PCP and who have negative results from ≥2 bonchoscopies, and among patients whose clinical course is at variance with laboratory-confirmed PCP.
Histologic diagnosis
Pneumocystis cannot reliably be cultured ex vivo, and so diagnosis of PCP is Use of Pneumocystis-specific monoclonal antibodies and immunofluorescence has greater diagnostic sensitivity than histologic stains, but is more expensive and requires specific laboratory expertise.
Molecular detection tests
Detection of Pneumocystis-specific DNA using the polymerase chain reaction 
Empirical therapy
Empirical therapy for HIV-infected patients presenting with symptoms, chest radiographic and arterial blood gas abnormalities typical of PCP is used in healthcare settings that lack diagnostic facilities. This strategy is possible if a patient with a CD4 <200 cells/uL (or stigmata of immune suppression) has typical radiological abnormalities, is not receiving Pneumocystis prophylaxis or cART, and has a low probability of other (opportunistic) infections, such as tuberculosis [38] .
Treatment
An assessment of the severity of the pneumonia, using the results of arterial Severity stratification also identifies patients who will benefit from adjunctive glucocorticoids (see below).
Patients with glucose 6-phosphate dehydrogenase deficiency should not receive TMP-SMX, dapsone, or primaquine as they increase the risk of hemolysis.
Trimethoprim-sulfamethoxazole
Trimethoprim-sulfamethoxazole (TMP-SMX), [Bactrim, Bactrimel, Cotrimoxazole, Cotrim, Septra, Septrin, Sulfatrim,Trisul] (20 mg/kg daily of TMP and 100 mg/kg daily of SMX ) given in two to four divided doses orally or intravenously is first choice therapy for PCP of all grades of severity; this drug combination acts by inhibiting folic acid metabolism. In HIV-infected patients treatment is given for 21 days because shorter courses are associated with treatment failure. In patients with moderate or severe disease, TMP-SMX is given intravenously for the first 7-10 days, then orally; in patients with mild disease oral TMP-SMX may be given throughout.
This treatment regimen is effective in 70-80% of patients. Adverse reactions to TMP-SMX, which are usually first evident at 6-14 days of treatment, are common and include neutropenia and anemia in ≤40% of patients, rash in 25%, fever in >30% and abnormal liver function tests in approximately 10% [49] [50].
Co-administration of folic or folinic acid does not reduce or prevent hematologic toxicity and may be associated with increased therapeutic failure. Dose reduction of TMP-SMX, to 75% of the dose given above, is associated with a reduced toxicity profile but may be associated with reduced efficacy. It is not clear why there is such a high frequency of adverse reactions to TMP-SMX among HIVinfected patients compared to patients immunosuppressed by other causes, but it may be due to HIV-induced changes in acetylator status, accumulation of toxic metabolites such as hydroxylamines, or to glutathione deficiency.
Alternative therapy
Several other treatments are available if TMP-SMX is not tolerated by the patient or if treatment fails [17] .
Clindamycin and primaquine
This combination was originally only used to "salvage" patients with mild and 
Nebulized pentamidine
This has no role in treatment of PCP.
Adjunctive Corticosteroids
In HIV-infected patients with moderate and severe PCP adjunctive therapy with corticosteroids has been shown to reduce the likelihood of respiratory failure (by half) and death (by one-third). Corticosteroids probably act by reducing the body's intrapulmonary inflammatory response to Pneumocystis. It is recommended that glucocorticoids are given to HIV-infected patients with proven or suspected PCP who have a PaO2 <70mmHg (< 9.3 kPa) or A aO2 >35 mmHg (>4.7 kPa) [17] Corticosteroid treatment should begin at the start of specific anti Pneumocystis therapy. In some patients treatment will begin on a empiric basis and the diagnosis should be confirmed as soon as practicable. Regimens include oral prednisolone 40 mg twice daily for 5 days, thereafter 40 mg once daily for days 6-10 and then 10 further days of 20 mg daily and intravenous methylprednisolone at 75% of these doses [17] . There is no evidence that adjunctive corticosteroids are of benefit in patients with mild PCP. Patients receiving adjunctive corticosteroids should be monitored for hyperglycemia. In the long term patients receiving this intervention are at greater risk of developing avascular necrosis of the hip.
General management
In the first few days of of treatment HIV-infected patients with PCP may experience a deterioration in their clinical condition, with worsening of the chest radiograph and oxygenation. This is thought to arise either from the host inflammatory response to (Table) . Additionally, is important to perform bronchoscopy if the diagnosis is empiric, and to treat any co-pathology already detected in BAL fluid.
All 
Stopping prophylaxis
The widespread availability and uptake of cART in North America, Europe and Australasia has been associated with marked reductions in incidence of many opportunistic infections, including PCP, hospital admissions and mortality from HIV infection. In most patients, within a few weeks of starting cART, there are rapid decreases in plasma HIV RNA and, in parallel, increases in CD4 counts. The US Public Health Service/Infectious Disease Society of America recommend that primary prophylaxis against PCP may be discontinued in HIV-infected persons who respond to cART with an increase in CD4 counts to > months [17] . Many of these patients will also have reduction in HIV RNA to below the limit of detection. Withdrawal of secondary prophylaxis may be carried out, using these criteria. If, despite cART, the CD4 lymphocyte count falls to < and/or the plasma HIV RNA "load" rises, then prophylaxis should be re-instituted using the criteria for primary prophylaxis. Clearly, close patient monitoring is needed to detect any such changes rapidly.
Recent data accrued from a cohort study, a retrospective review and a case series show a low incidence of PCP among patients who discontinue or never start PCP prophylaxis, who received ART and had CD4 counts between 100-200 cells/µL and plasma HIV viral loads <50-400 copies/mL [62] [63] [64] . Although these data support discontinuation of primary PCP prophylaxis in certain patients with CD4
counts between 100-200 cells/µL, with some experts recommending this approach for their patients, this intervention has not yet been widely adopted [17] .
Summary
The 
